Lawrence S Young

Q: What Schools Are Affiliated With Lawrence S Young

Lawrence S Young is affiliated with the following schools: University of Warwick, University of California, Berkeley, University of Oxford, Stanford University, University of Birmingham

Lawrence S Young's AcademicInfluence.com Rankings

Lawrence S Young

Engineering

#3561

World Rank

#4660

Historical Rank

Electrical Engineering

#806

World Rank

#874

Historical Rank

engineering Degrees

Lawrence S Young

Computer Science

#4570

World Rank

#4822

Historical Rank

Computational Linguistics

#466

World Rank

#474

Historical Rank

Machine Learning

#941

World Rank

#955

Historical Rank

Artificial Intelligence

#1160

World Rank

#1181

Historical Rank

computer-science Degrees

Download Badge

Engineering
Computer Science

Lawrence S Young's Degrees

PhD Computer Science Stanford University
Masters Electrical Engineering University of California, Berkeley
Bachelors Computer Engineering University of California, Berkeley

Similar Degrees You Can Earn

Best Online PhD of Computer Science (Doctorates) 2026

Why Is Lawrence S Young Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Lawrence S Young's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Epstein–Barr virus: 40 years on (2004) (2089)
The natural history of cervical HPV infection: unresolved issues (2007) (934)
Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study (2001) (883)
Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. (1989) (813)
Differences in B cell growth phenotype reflect novel patterns of Epstein‐Barr virus latent gene expression in Burkitt's lymphoma cells. (1987) (770)
Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease (1991) (719)
Epstein–Barr virus and oncogenesis: from latent genes to tumours (2003) (551)
Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts (1992) (529)
Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state (1994) (523)
Epstein–Barr virus: more than 50 years old and still providing surprises (2016) (494)
Epstein-Barr virus gene expression in nasopharyngeal carcinoma. (1988) (485)
Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. (1999) (429)
Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells (1993) (405)
Influence of the Epstein-Barr virus nuclear antigen EBNA 2 on the growth phenotype of virus-transformed B cells (1987) (383)
EpsteinBarr virus latent membrane protein inhibits human epithelial cell differentiation (1990) (376)
Activation of the p38 Mitogen-activated Protein Kinase Pathway by Epstein-Barr Virus-encoded Latent Membrane Protein 1 Coregulates Interleukin-6 and Interleukin-8 Production* (1999) (372)
Viral gene therapy strategies: from basic science to clinical application (2006) (331)
Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man (1991) (324)
Activation of the cJun N-terminal kinase (JNK) pathway by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1) (1998) (303)
Epstein-Barr Virus Latent Membrane Protein 1 (LMP1) Activates the Phosphatidylinositol 3-Kinase/Akt Pathway to Promote Cell Survival and Induce Actin Filament Remodeling* (2003) (298)
Epstein – Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-κB pathway involving TNF receptor-associated factors (1997) (297)
Monoclonal antibodies to the latent membrane protein of Epstein-Barr virus reveal heterogeneity of the protein and inducible expression in virus-transformed cells. (1987) (286)
Epstein-Barr virus-encoded EBNA1 inhibits the canonical NF-κB pathway in carcinoma cells by inhibiting IKK phosphorylation (2010) (274)
The role of the EBV-encoded latent membrane proteins LMP1 and LMP2 in the pathogenesis of nasopharyngeal carcinoma (NPC). (2012) (272)
A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma (2009) (271)
The polymerase chain reaction: a new epidemiological tool for investigating cervical human papillomavirus infection. (1989) (262)
Differentiation-associated expression of the Epstein-Barr virus BZLF1 transactivator protein in oral hairy leukoplakia (1991) (262)
The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. (1996) (257)
Epstein-Barr virus and nasopharyngeal carcinoma (2014) (243)
EPSTEIN–BARR VIRUS (EBV) INFECTION IN INFECTIOUS MONONUCLEOSIS: VIRUS LATENCY, REPLICATION AND PHENOTYPE OF EBV‐INFECTED CELLS (1997) (238)
Epstein-Barr Virus-Encoded Latent Membrane Protein 1 Activates the JNK Pathway through Its Extreme C Terminus via a Mechanism Involving TRADD and TRAF2 (1999) (233)
CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr Virus-encoded LMP1: involvement of TRAF3 as a common mediator. (1996) (223)
Epstein–Barr virus infection and replication in a human epithelial cell system (1992) (221)
Analysis of Epstein-Barr virus gene polymorphisms in normal donors and in virus-associated tumors from different geographic locations. (1996) (204)
High incidence of cervical human papillomavirus infection in women during their first sexual relationship (2002) (200)
HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2 (1993) (199)
Genome Diversity of Epstein-Barr Virus from Multiple Tumor Types and Normal Infection (2015) (197)
New type B isolates of Epstein-Barr virus from Burkitt's lymphoma and from normal individuals in endemic areas. (1987) (196)
CD40 Activation Induces Apoptosis in Cultured Human Hepatocytes via Induction of Cell Surface Fas Ligand Expression and Amplifies Fas-mediated Hepatocyte Death during Allograft Rejection (1999) (194)
CD40 Induces Apoptosis in Carcinoma Cells through Activation of Cytotoxic Ligands of the Tumor Necrosis Factor Superfamily (2000) (191)
Patterns of Epstein-Barr virus infection in non-neoplastic lymphoid tissue. (1992) (189)
Immunotherapy in hepatocellular carcinoma (2000) (183)
EPSTEIN-BARR VIRUS RECEPTORS ON HUMAN PHARYNGEAL EPITHELIA (1986) (183)
Epstein-Barr virus infection in oral hairy leukoplakia: virus replication in the absence of a detectable latent phase. (1991) (183)
Constitutive activation of phosphatidyl‐inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR (2005) (182)
Distinction between Epstein-Barr virus type A (EBNA 2A) and type B (EBNA 2B) isolates extends to the EBNA 3 family of nuclear proteins (1989) (182)
Epstein–Barr virus and carcinomas: Undifferentiated carcinomas but not squamous cell carcinomas of the nasopharynx are regularly associated with the virus (1991) (179)
Expression of the Epstein-Barr virus-encoded Epstein-Barr virus nuclear antigen 1 in Hodgkin's lymphoma cells mediates Up-regulation of CCL20 and the migration of regulatory T cells. (2008) (176)
Distribution and phenotype of Epstein-Barr virus-harboring cells in Hodgkin's disease. (1992) (175)
The Epstein-Barr virus and its association with human cancers. (1999) (175)
Monoclonal antibodies directed against the Epstein-Barr virus-encoded nuclear antigen 1 (EBNA1): immunohistologic detection of EBNA1 in the malignant cells of Hodgkin's disease. (1994) (174)
Pseudomonas aeruginosa infections. (2008) (162)
Prognostic impact of tumour‐infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma (2009) (158)
CD40 and epithelial cells: across the great divide. (1998) (158)
Epstein-Barr virus persistence and virus-associated tumours (1994) (153)
Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma. (1995) (152)
Identification of a human epithelial cell surface protein sharing an epitope with the C3d/epstein‐barr virus receptor molecule of B lymphocytes (1989) (152)
Analysis of major histocompatibility complex class I, TAP expression, and LMP2 epitope sequence in Epstein-Barr virus-positive Hodgkin's disease. (1998) (148)
Human epithelial cell expression of an Epstein-Barr virus receptor. (1987) (145)
Expression of Epstein-Barr virus genes and of lymphocyte activation molecules in undifferentiated nasopharyngeal carcinomas. (1992) (142)
Epstein-Barr virus (EBV) and its associated human cancers--genetics, epigenetics, pathobiology and novel therapeutics. (2006) (136)
Immunohistochemical demonstration of the Epstein–Barr virus‐encoded latent membrane protein in paraffin sections of Hodgkin's disease (1992) (135)
Transcripts from the Epstein-Barr virus BamHI A fragment are detectable in all three forms of virus latency (1993) (132)
Three transcriptionally distinct forms of Epstein-Barr virus latency in somatic cell hybrids: cell phenotype dependence of virus promoter usage. (1992) (131)
Epstein-Barr virus DNA and latent gene products in Ki-1 (CD30)-positive anaplastic large cell lymphomas. (1991) (129)
Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer. (2004) (127)
Anti-proliferative activity and mechanism of action of titanocene dichloride. (1998) (126)
Expression of the cellular FLICE-inhibitory protein (c-FLIP) protects Hodgkin's lymphoma cells from autonomous Fas-mediated death. (2004) (124)
CD40 activation‐induced, Fas‐dependent apoptosis and NF‐κB/AP‐1 signaling in human intrahepatic biliary epithelial cells (2001) (123)
Down-regulation of the TGF-beta target gene, PTPRK, by the Epstein-Barr virus encoded EBNA1 contributes to the growth and survival of Hodgkin lymphoma cells. (2008) (123)
Modulation of the Cell Growth Regulator mTOR by Epstein-Barr Virus-Encoded LMP2A (2005) (123)
Expression of immune regulatory molecules in Epstein-Barr virus-associated nasopharyngeal carcinomas with prominent lymphoid stroma. Evidence for a functional interaction between epithelial tumor cells and infiltrating lymphoid cells. (1995) (123)
Epstein-Barr virus and carcinogenesis: beyond Burkitt's lymphoma. (2009) (120)
The expression and function of Epstein-Barr virus encoded latent genes (2000) (120)
Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene. (1997) (120)
Epstein-Barr virus-specific cytotoxic T-cell recognition of transfectants expressing the virus-coded latent membrane protein LMP (1988) (118)
Induction of autotaxin by the Epstein-Barr virus promotes the growth and survival of Hodgkin lymphoma cells. (2005) (117)
Expression of Epstein–Barr virus replicative proteins in aids‐related non‐Hodgkin's lymphoma cells (1991) (116)
Epstein-Barr Virus-Encoded LMP1 Regulates Epithelial Cell Motility and Invasion via the ERK-MAPK Pathway (2008) (114)
Epstein–Barr virus-encoded EBNA1 regulates cellular gene transcription and modulates the STAT1 and TGFβ signaling pathways (2007) (113)
Epstein-Barr virus-encoded EBNA1 modulates the AP-1 transcription factor pathway in nasopharyngeal carcinoma cells and enhances angiogenesis in vitro. (2008) (112)
Epstein-Barr virus-encoded LMP2A regulates viral and cellular gene expression by modulation of the NF-kappaB transcription factor pathway. (2004) (110)
Two families of sequences in the small RNA-encoding region of Epstein-Barr virus (EBV) correlate with EBV types A and B (1989) (109)
Analysis of epstein‐barr virus infection in nasopharyngeal biopsies from a group at high risk of nasopharyngeal carcinoma (2009) (109)
NITROREDUCTASE: A PRODRUG‐ACTIVATING ENZYME FOR CANCER GENE THERAPY (2004) (107)
Epstein–Barr virus-encoded latent infection membrane protein 1 regulates the processing of p100 NF-κB2 to p52 via an IKKγ/NEMO-independent signalling pathway (2003) (106)
Immunohistochemical Detection of the Epstein-Barr Virus–Encoded Latent Membrane Protein 2A in Hodgkin's Disease and Infectious Mononucleosis (1997) (104)
The Epstein-Barr virus carrier state: dominance of a single growth-transforming isolate in the blood and in the oropharynx of healthy virus carriers. (1991) (103)
The role of the CD40 pathway in the pathogenesis and treatment of cancer. (2004) (101)
Inhibition of Human Breast Carcinoma Growth by a Soluble Recombinant Human CD40 Ligand (1999) (100)
P53 overexpression and Epstein‐Barr virus infection in undifferentiated and squamous cell nasopharyngeal carcinomas (1993) (99)
Role of the Epstein-Barr virus-encoded latent membrane protein-1, LMP1, in the pathogenesis of nasopharyngeal carcinoma. (2009) (99)
Cigarette smoking is an independent risk factor for cervical intraepithelial neoplasia in young women: A longitudinal study☆ (2010) (96)
A Phase I/II Clinical Trial in Localized Prostate Cancer of an Adenovirus Expressing Nitroreductase with CB1984. (2009) (94)
Efficient nonviral transfection of dendritic cells and their use for in vivo immunization (2000) (94)
The EBV-encoded Latent Membrane Proteins, LMP2A and LMP2B, Limit the Actions of Interferon by Targeting Interferon Receptors for Degradation (2009) (91)
Contributions of the Epstein-Barr Virus EBNA1 Protein to Gastric Carcinoma (2011) (90)
Bmi-1 is induced by the Epstein-Barr virus oncogene LMP1 and regulates the expression of viral target genes in Hodgkin lymphoma cells. (2007) (90)
Oncogenic human papillomavirus imposes an instructive pattern of DNA methylation changes which parallel the natural history of cervical HPV infection in young women. (2012) (89)
Inhibition of Phosphatidylinositol 3-Kinase- and ERK MAPK-regulated Protein Synthesis Reveals the Pro-apoptotic Properties of CD40 Ligation in Carcinoma Cells* (2004) (89)
The ATM tumour suppressor gene is down‐regulated in EBV‐associated nasopharyngeal carcinoma (2009) (87)
Different patterns of Epstein-Barr virus gene expression and of cytotoxic T-cell recognition in B-cell lines infected with transforming (B95.8) or nontransforming (P3HR1) virus strains (1988) (87)
Disruption of the E2 gene is a common and early event in the natural history of cervical human papillomavirus infection: a longitudinal cohort study. (2009) (87)
Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector‐mediated expression of E. coli nitroreductase (2000) (85)
Expression of cytokine and chemokine genes in Epstein–Barr virus‐associated nasopharyngeal carcinoma: comparison with Hodgkin's disease (2001) (84)
Activation of Epstein-Barr virus replication in Hodgkin and Reed-Sternberg cells. (1991) (83)
Human papillomavirus type 18 and rapidly progressing cervical intraepithelial neoplasia (2003) (82)
The Epstein-Barr Virus-Encoded LMP2A and LMP2B Proteins Promote Epithelial Cell Spreading and Motility (2005) (82)
BHRF1, a viral homologue of the Bcl-2 oncogene, disturbs epithelial cell differentiation. (1995) (81)
Epstein-Barr virus (EBV) in infectious mononucleosis: detection of the virus in tonsillar B lymphocytes but not in desquamated oropharyngeal epithelial cells (2000) (81)
Effect of Epstein-Barr virus infection on response to chemotherapy and survival in Hodgkin's disease. (1999) (80)
TRAF6 Is Required for TRAF2-Dependent CD40 Signal Transduction in Nonhemopoietic Cells (2005) (80)
Identification of functional differences between prototype Epstein-Barr virus-encoded LMP1 and a nasopharyngeal carcinoma-derived LMP1 in human epithelial cells. (2000) (78)
Clinical Approach to Infection in the Compromised Host (2002) (78)
Reactivity with A monoclonal antibody to Epstein-Barr virus (EBV) nuclear antigen 1 defines a subset of aggressive breast cancers in the absence of the EBV genome. (2003) (78)
Epstein–Barr virus infection: basis of malignancy and potential for therapy (2001) (77)
Activation of the FGFR1 signalling pathway by the Epstein–Barr virus‐encoded LMP1 promotes aerobic glycolysis and transformation of human nasopharyngeal epithelial cells (2015) (75)
Epstein-Barr virus-encoded EBNA1 regulates cellular gene transcription and modulates the STAT1 and TGFbeta signaling pathways. (2007) (74)
In vitro production of stable Epstein-Barr virus-positive epithelial cell clones which resemble the virus:cell interaction observed in nasopharyngeal carcinoma. (1996) (73)
Activation of CD40 in Cervical Carcinoma Cells Facilitates CTL Responses and Augments Chemotherapy-Induced Apoptosis1 (2004) (72)
Epstein-Barr virus gene expression in malignant lymphomas induced by experimental virus infection of cottontop tamarins (1989) (72)
Interleukin 6 expression by Hodgkin/Reed–Sternberg cells is associated with the presence of ‘B’ symptoms and failure to achieve complete remission in patients with advanced Hodgkin's disease (2002) (72)
Epstein–Barr virus latent membrane protein-1 (LMP1) signalling is distinct from CD40 and involves physical cooperation of its two C-terminus functional regions (1998) (71)
TRAF1 Is a Critical Regulator of JNK Signaling by the TRAF-Binding Domain of the Epstein-Barr Virus-Encoded Latent Infection Membrane Protein 1 but Not CD40 (2003) (70)
Constitutive activation of the CD40 pathway promotes cell transformation and neoplastic growth (2005) (69)
EBV gene expression and regulation (2007) (69)
The role of repetitive DNA sequences in the size variation of Epstein-Barr virus (EBV) nuclear antigens, and the identification of different EBV isolates using RFLP and PCR analysis. (1995) (69)
Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand. (1999) (69)
Single-cell transcriptomic analysis defines the interplay between tumor cells, viral infection, and the microenvironment in nasopharyngeal carcinoma (2020) (68)
Epstein–Barr virus induction of the Hedgehog signalling pathway imposes a stem cell phenotype on human epithelial cells (2013) (67)
CD40 activation in epithelial ovarian carcinoma cells modulates growth, apoptosis, and cytokine secretion (2002) (67)
Inhibition of Metalloproteinase Cleavage Enhances the Cytotoxicity of Fas Ligand1 (2003) (65)
Pituitary gonadotropin-releasing hormone receptor regulation in mice. II: Females. (1984) (65)
BHRF1, a viral homologue of the Bcl-2 oncogene, is conserved at both the sequence and functional level in different Epstein-Barr virus isolates. (1997) (64)
Pituitary tumor transforming gene binding factor: a novel transforming gene in thyroid tumorigenesis. (2005) (64)
Epstein‐Barr virus‐transformed human precursor B cell lines: altered growth phenotype of lines with germline or rearranged but nonexpressed heavy chain genes (1987) (63)
Epstein‐Barr Virus and Carcinomas Expression of the Viral Genome in an Undifferentiated Gastric Carcinoma (1992) (62)
CD40 expression in bladder cancer (1999) (62)
Expression of Escherichia coli B nitroreductase in established human tumor xenografts in mice results in potent antitumoral and bystander effects upon systemic administration of the prodrug CB1954 (2000) (61)
Frequent epigenetic inactivation of the RASSF1A tumor suppressor gene in Hodgkin's lymphoma (2004) (61)
The Oncogenic Protein Kinase Tpl-2/Cot Contributes to Epstein-Barr Virus-Encoded Latent Infection Membrane Protein 1-Induced NF-κB Signaling Downstream of TRAF2 (2002) (61)
Inhibition of the LKB1–AMPK pathway by the Epstein–Barr virus‐encoded LMP1 promotes proliferation and transformation of human nasopharyngeal epithelial cells (2013) (60)
Absence of Epstein-Barr virus DNA in the tumor cells of European hepatocellular carcinoma. (2003) (60)
A Global View of the Oncogenic Landscape in Nasopharyngeal Carcinoma: An Integrated Analysis at the Genetic and Expression Levels (2012) (58)
Viruses and apoptosis. (1997) (57)
The promise and potential hazards of adenovirus gene therapy (2001) (56)
Immunohistochemical detection of the Epstein-Barr virus-encoded latent membrane protein 2A in Hodgkin's disease and infectious mononucleosis. (1997) (56)
Detection of HPV 6 and 11 in tumours of the upper respiratory tract using the polymerase chain reaction. (1990) (56)
The role of cellular flice inhibitory protein (c-FLIP) in the pathogenesis and treatment of cancer (2006) (55)
Epstein–Barr virus latent membrane protein 1 (LMP1) upregulates Id1 expression in nasopharyngeal epithelial cells (2004) (55)
BCL2 expression predicts survival in patients receiving synchronous chemoradiotherapy in advanced transitional cell carcinoma of the bladder. (2003) (55)
Combined adenovirus-mediated nitroreductase gene delivery and CB1954 treatment: a well-tolerated therapy for established solid tumors. (2001) (53)
The transmembrane domains of the EBV-encoded latent membrane protein 1 (LMP1) variant CAO regulate enhanced signalling activity. (2001) (52)
An etiological role for the Epstein-Barr virus in the pathogenesis of classical Hodgkin lymphoma. (2019) (51)
IN SITU DETECTION OF THE EPSTEIN–BARR VIRUS‐ENCODED NUCLEAR ANTIGEN 1 IN ORAL HAIRY LEUKOPLAKIA AND VIRUS‐ASSOCIATED CARCINOMAS (1996) (51)
A phase I/II clinical trial in localized prostate cancer of an adenovirus expressing nitroreductase with CB1954 [correction of CB1984]. (2009) (51)
Epstein-Barr virus-encoded latent infection membrane protein 1 regulates the processing of p100 NF-kappaB2 to p52 via an IKKgamma/NEMO-independent signalling pathway. (2003) (51)
Epstein-Barr virus and carcinomas: rare association of the virus with gastric adenocarcinomas. (1993) (51)
Phase I/II trial of a dendritic cell vaccine transfected with DNA encoding melan A and gp100 for patients with metastatic melanoma (2011) (51)
The Role of the Epstein-Barr virus in human disease. (2002) (51)
The effect of Epstein-Barr virus status on outcome in age- and sex-defined subgroups of patients with advanced Hodgkin's disease. (2003) (50)
Epstein-Barr Virus Induces Cellular Transcription Factors to Allow Active Expression of EBER Genes by RNA Polymerase III* (2006) (50)
Epstein-Barr virus, lymphomas and Hodgkin's disease. (1992) (50)
Aspects of the management of shock. (1980) (50)
Differential induction of nuclear factor-kappaB and activator protein-1 activity after CD40 ligation is associated with primary human hepatocyte apoptosis or intrahepatic endothelial cell proliferation. (2003) (50)
Detection of Epstein–Barr virus antigens and DNA in major and minor salivary glands using immunocytochemistry and polymerase chain reaction: Possible relationship with Sjogren's syndrome (1991) (49)
CD40 mediated human cholangiocyte apoptosis requires JAK2 dependent activation of STAT3 in addition to activation of JNK1/2 and ERK1/2. (2006) (49)
Demonstration of multiple HPV types in normal cervix and in cervical squamous cell carcinoma using the polymerase chain reaction on paraffin wax embedded material. (1990) (49)
Analysis of human papillomavirus type 16 E6-E7 transcription in cervical carcinomas and normal cervical epithelium using the polymerase chain reaction. (1990) (49)
CD40 Ligand-Induced Carcinoma Cell Death: A Balance between Activation of TNFR-Associated Factor (TRAF) 3-Dependent Death Signals and Suppression of TRAF6-Dependent Survival Signals (2009) (48)
South Asian ethnicity and material deprivation increase the risk of Epstein-Barr virus infection in childhood Hodgkin's disease (2001) (47)
Epstein-Barr virus infection and the pathogenesis of malignant lymphomas. (1997) (46)
Proapoptotic genes BAX and CD40L are predictors of survival in transitional cell carcinoma of the bladder (2003) (45)
Elevated expression of ICAM1 (CD54) and minimal expression of LFA3 (CD58) in epstein‐barr‐virus‐positive nasopharyngeal carcinoma cells (1992) (44)
The Epstein-Barr virus encoded latent membrane protein 2A augments signaling from latent membrane protein 1. (2001) (43)
The contribution of the Epstein-Barr virus to the pathogenesis of childhood lymphomas. (2010) (43)
Gene therapy strategies for colon cancer. (2000) (43)
Epstein‐Barr virus infection and malignant lymphomas in liver transplant recipients (1997) (43)
Smoking initiation is followed by the early acquisition of epigenetic change in cervical epithelium: a longitudinal study (2011) (43)
EPSTEIN-BARR VIRUS TYPE 1 (EBV-1) AND 2 (EBV-2) DIFFER IN THEIR EBNA-3A, EBNA-3B, AND EBNA-3C GENES (1990) (43)
The polycomb group proteins, BMI-1 and EZH2, are tumour-associated antigens (2006) (42)
Upregulation of Id1 by Epstein-Barr Virus-encoded LMP1 confers resistance to TGFβ-mediated growth inhibition (2010) (42)
Non‐Hodgkin's lymphoma, coeliac disease, and Epstein–Barr virus: A study of 13 cases of enteropathy‐associated T‐ and B‐cell lymphoma (1995) (41)
Demonstration of Epstein-Barr virus in primary brain lymphoma by in situ DNA hybridisation in paraffin wax embedded tissue. (1990) (41)
Functional Differences between BHRF1, the Epstein-Barr Virus-Encoded Bcl-2 Homologue, and Bcl-2 in Human Epithelial Cells (1998) (40)
Carbonic anhydrase IX, a marker of hypoxia: correlation with clinical outcome in transitional cell carcinoma of the bladder. (2004) (40)
Junctional adhesion molecule-A is co-expressed with HER2 in breast tumors and acts as a novel regulator of HER2 protein degradation and signaling (2013) (40)
EBV‐encoded miRNAs target ATM‐mediated response in nasopharyngeal carcinoma (2018) (39)
Epstein-Barr virus and carcinomas (1993) (39)
Adenosine 3',5'-monophosphate derivatives increase gonadotropin-releasing hormone receptors in cultured pituitary cells. (1984) (39)
Is Human Papillomavirus Viral Load a Clinically Useful Predictive Marker? A Longitudinal Study (2010) (38)
Pituitary gonadotropin-releasing hormone receptor regulation in the hypogonadotrophic hypogonadal (hpg) mouse. (1983) (37)
Expression of the tumour necrosis factor receptor‐associated factors 1 and 2 in Hodgkin's disease (2001) (37)
Prolonged phenotypic, functional, and molecular change in group I Burkitt lymphoma cells on short-term exposure to CD40 ligand. (1998) (37)
Overexpression of p53 in Hodgkin's disease: Lack of correlation with Epstein–Barr virus infection (1993) (37)
Latent Epstein-Barr virus infection in cottontop tamarins. A possible model for Epstein-Barr virus infection in humans. (1994) (37)
Mechanism of cell death induced by the novel enzyme-prodrug combination, nitroreductase/CB1954, and identification of synergism with 5-fluorouracil (2003) (37)
Cancer gene-therapy: clinical trials. (2006) (36)
Prolonged Phenotypic, Functional, and Molecular Change in Group I Burkitt Lymphoma Cells on Short-Term Exposure to CD40 Ligand (1998) (36)
Epstein-Barr virus-encoded LMP1 induces a hyperproliferative and inflammatory gene expression programme in cultured keratinocytes. (2008) (35)
Activation of sterol regulatory element‐binding protein 1 (SREBP1)‐mediated lipogenesis by the Epstein–Barr virus‐encoded latent membrane protein 1 (LMP1) promotes cell proliferation and progression of nasopharyngeal carcinoma (2018) (35)
Epstein-Barr virus-associated cancers: aetiology and treatment. (2003) (33)
Low prevalence of Epstein–Barr virus in incident gastric adenocarcinomas from the United Kingdom (2002) (32)
Whole-genome profiling of nasopharyngeal carcinoma reveals viral-host co-operation in inflammatory NF-κB activation and immune escape (2021) (31)
Pituitary gonadotropin-releasing hormone receptor regulation in mice. I: Males. (1984) (31)
The Epstein-Barr virus encoded LMP1 oncoprotein modulates cell adhesion via regulation of activin A/TGFβ and β1 integrin signalling (2016) (31)
The EBV-Encoded Oncoprotein, LMP1, Induces an Epithelial-to-Mesenchymal Transition (EMT) via Its CTAR1 Domain through Integrin-Mediated ERK-MAPK Signalling (2018) (31)
EPstein‐barr virus in inflammatory diseases of the liver and liver allografts: An in situ hybridization study (1994) (31)
The Role of EBV-Encoded LMP1 in the NPC Tumor Microenvironment: From Function to Therapy (2021) (30)
Epstein-Barr virus: biology and disease. (1997) (29)
ONCOGENIC VIRUSES AND CERVICAL CANCER (1989) (29)
High-level, beta-catenin/TCF-dependent transgene expression in secondary colorectal cancer tissue. (2001) (29)
Localization of Epstein-Barr virus in Castleman's disease by in situ hybridization and immunohistochemistry. (1995) (29)
Role of Sexual Behavior in the Acquisition of Asymptomatic Epstein-Barr Virus Infection: A Longitudinal Study (2005) (29)
Epstein-Barr virus-encoded EBNA1 enhances RNA polymerase III-dependent EBER expression through induction of EBER-associated cellular transcription factors (2010) (28)
Epstein-Barr virus at 50—future perspectives (2014) (27)
C4b Binding Protein Binds to CD154 Preventing CD40 Mediated Cholangiocyte Apoptosis: A Novel Link between Complement and Epithelial Cell Survival (2007) (26)
Apoptosis of malignant cells in Hodgkin's disease is related to expression of the cdk inhibitor p27KIP1 (2000) (26)
Evidence for a pituitary site of gonadal steroid stimulation of GnRH receptors in female mice. (1985) (26)
Infection in the compromised host. (1981) (26)
Multiple forms of rat liver type I topoisomerase. (1983) (26)
Effect of material deprivation on Epstein–Barr virus infection in Hodgkin's disease in the West Midlands (1999) (25)
Gonadotrophin releasing hormone receptor regulation in relationship to gonadotrophin secretion. (1985) (25)
An interferon-γ ELISPOT and immunohistochemical investigation of cytotoxic T lymphocyte-mediated tumour immunity in patients with paraneoplastic cerebellar degeneration and anti-Yo antibodies (2004) (25)
Epstein-Barr virus and apoptosis: viral mimicry of cellular pathways. (1999) (24)
Epstein-Barr virus and epithelial cells: a possible role for the virus in the development of cervical carcinoma. (1988) (24)
HOXC11–SRC-1 regulation of S100beta in cutaneous melanoma: new targets for the kinase inhibitor dasatinib (2011) (23)
Immune enhancement of nitroreductase‐induced cytotoxicity: Studies using a bicistronic adenovirus vector (2003) (23)
CD154 Tone Sets the Signaling Pathways and Transcriptome Generated in Model CD40-Pluricompetent L3055 Burkitt’s Lymphoma Cells1 (2007) (22)
Epstein-Barr virus gene expression in post-transplant lymphoproliferative disorders (2004) (22)
Increased gonadotrophin releasing hormone receptors on pituitary gonadotrophs: effect on subsequent LH secretion (1985) (22)
Human papillomavirus infection and risk of progression of epithelial abnormalities of the cervix. (1996) (20)
Epstein-Barr virus gene expression in Hodgkin's disease. (1991) (20)
CD40 ligand induced cytotoxicity in carcinoma cells is enhanced by inhibition of metalloproteinase cleavage and delivery via a conditionally-replicating adenovirus (2010) (19)
DNA tumour viruses promote tumour cell invasion and metastasis by deregulating the normal processes of cell adhesion and motility. (2008) (19)
The Dynamic Roles of TGF-β Signalling in EBV-Associated Cancers (2018) (19)
Evidence of disrupted high-risk human papillomavirus DNA in morphologically normal cervices of older women (2016) (19)
Role of GnRH in the regulation of pituitary GnRH receptors in female mice. (1985) (19)
Activation of SREBP1-mediated lipogenesis by the Epstein-Barr Virus-encoded LMP1 promotes cell proliferation and progression of nasopharyngeal carcinoma. (2018) (18)
Pituitary and gonadal function in hypogonadotrophic hypogonadal (hpg) mice bearing hypothalamic implants. (1985) (18)
The expression of the retinoblastoma gene product Rb1 in primary and adenovirus-transformed human cells. (1989) (18)
Epstein-Barr virus nuclear antigen 1 (EBNA1) induced cytotoxicity in epithelial cells is associated with EBNA1 degradation and processing. (2003) (17)
Studies on the regulation and specificity of the DNA-untwisting enzyme. (1979) (17)
Sensitisation of human ovarian cancer cells to killing by the prodrug CB1954 following retroviral or adenoviral transfer of the E. coli nitroreductase gene. (1998) (16)
Epstein-Barr virus infection of CR2-transfected epithelial cells reveals the presence of MHC class II on the virion. (1995) (16)
Expression of tumor necrosis factor receptor–associated factor 1 in nasopharyngeal carcinoma: Possible upregulation by Epstein‐Barr virus latent membrane protein 1 (2004) (16)
Overexpression of wild-type p53 and c-Myc in human fetal cells transformed with adenovirus early region 1. (1993) (16)
Pituitary gonadotrophin-releasing hormone receptor up-regulation in vitro: dependence on calcium and microtubule function. (1985) (16)
Frequent expression of the tumor necrosis factor receptor-associated factor 1 in latent membrane protein 1-positive posttransplant lymphoproliferative disease and HIV-associated lymphomas. (2001) (16)
NF-kappaB overrides the apoptotic program of TNF receptor 1 but not CD40 in carcinoma cells. (2005) (15)
The expression of the Epstein-Barr virus nuclear antigen (EBNA-I) in oral hairy leukoplakia. (1997) (15)
Synthesis in vitro and application of biotinylated DNA probes for human papilloma virus type 16 by utilizing the polymerase chain reaction. (1990) (15)
Disruption of the E 2 Gene Is a Common and Early Event in the Natural History of Cervical Human Papillomavirus Infection : A Longitudinal Cohort Study (2009) (15)
The role of metabolic reprogramming in γ‐herpesvirus‐associated oncogenesis (2017) (15)
Epstein-Barr-virus infection and persistence: a B-cell marriage in sickness and in health (1999) (15)
Epstein-Barr virus latent genes in tumour cells of Hodgkin's disease (1991) (13)
The Epstein-Barr Virus-Encoded LMP2A and LMP2B Proteins Promote Epithelial Cell Spreading and Motility (2005) (13)
Combining gene and immunotherapy for prostate cancer (2008) (13)
Discovery of selective, antimetastatic and anti-cancer stem cell metallohelices via post-assembly modification† †Electronic supplementary information (ESI) available: Data created during this study are openly available from the University of Warwick Research Archive Portal (WRAP) (http://wrap.warwic (2019) (12)
Expression of the c‐fgr related transcripts in epstein‐barr virus‐associated malignancies (1988) (12)
Expression of B7 (CD80) and CD40 antigens and the CD40 ligand in Hodgkin's disease is independent of latent Epstein—Barr virus infection (1995) (12)
Interaction of the DNA untwisting enzyme with the SV40 nucleoprotein complex. (1978) (11)
Photoactive platinum(iv) complex conjugated to a cancer-cell-targeting cyclic peptide. (2019) (11)
An overview of infection in bone marrow transplant recipients. (1984) (10)
CD40L membrane retention enhances the immunostimulatory effects of CD40 ligation (2020) (10)
In vitro assays to study epithelial cell growth. (2001) (10)
The role of granulocyte transfusions in treating and preventing infection. (1983) (9)
EPSTEIN-BARR VIRUS/COMPLEMENT RECEPTOR AND EPITHELIAL CELLS (1989) (9)
Themed issue: the biology and pathology of the Epstein-Barr virus (2000) (9)
Gentamicin in the treatment of severe, hospital-acquired gram-negative infections. (1967) (9)
Advances in pathogenesis and precision medicine for nasopharyngeal carcinoma (2021) (9)
The Therapeutic Potential of Targeting BARF1 in EBV-Associated Malignancies (2020) (9)
Epstein-Barr virus gene expression in Hodgkin9s disease [letter; comment] (1991) (9)
Epstein-Barr virus and carcinomas: rare association of the virus with gastric adenocarcinomas (1993) (9)
Prospective serial study of viral change in the cervix and correlation with human papillomavirus genome status (1991) (9)
Gene therapy for colorectal cancer: therapeutic potential. (2001) (9)
Viruses and cancer risks: Outgrowth of Epstein-Barr virus-positive Burkitt's lymphoma in the immune host (1987) (9)
Epstein‐barr virus‐specific t‐cell recognition of B‐cell transformants expressing different ebna 2 antigens (1987) (8)
IMMUNOBIOLOGY Inhibition of Human Breast Carcinoma Growth by a Soluble Recombinant Human CD 40 Ligand (1999) (8)
Analysis of Epstein-Barr virus gene expression in lymphomas derived from normal human B cells grafted into SCID mice. (1990) (8)
Strategies for conjugating iridium(III) anticancer complexes to targeting peptides via copper-free click chemistry (2019) (8)
Seasonal differences in the onset of the EBV-positive and -negative forms of paediatric Hodgkin's lymphoma (2003) (8)
Homologous ligand induction of pituitary gonadotrophin-releasing hormone receptors in vivo is protein synthesis dependent (1984) (8)
Lack of evidence for an association of Epstein–Barr virus infection with breast carcinoma – authors' response (2003) (7)
A novel Epstein‐Barr virus subtype associated with nasopharyngeal carcinoma found in South China (2020) (6)
Intersection Between Race, Gender, and Sexual Risk: Implications for STI/HIV on HBCU Campuses (2007) (6)
Virus-directed enzyme prodrug therapy (VDEPT): A clinical trial of adenovirus-delivered nitroreductase (NTR) in combination with CB1954 in patients with primary or secondary liver cancer (2005) (6)
A clinical trial of virus-directed enzyme prodrug therapy (VDEPT) using adenovirus encoded nitroreductase (ntr) and CB1954 in patients with localized prostate cancer (PCa). (2004) (6)
Suicide gene therapy using adenovirus encoded nitroreductase and CB1954 in patients with locally relapsed prostate cancer (2005) (5)
A region of the Epstein-Barr virus nuclear antigen leader protein and adenovirus E1A are identical. (1988) (5)
Targeting cellular FLICE-like inhibitory protein as a novel approach to the treatment of Hodgkin’s lymphoma (2006) (5)
The Epstein-Barr Virus-Encoded EBNA1 Protein Activates the Bone Morphogenic Protein (BMP) Signalling Pathway to Promote Carcinoma Cell Migration (2020) (5)
Epstein-Barr Virus (2009) (5)
CD40 ligand gene therapy directly induces apoptosis in carcinomas (2007) (5)
Demonstration of Epstein-Barr virus in primary central nervous system lymphomas. (1991) (4)
PCR for the detection of cervical HPV16 infection: The need for standardization (1993) (4)
Epstein-Barr Virus Replication and Gene Expression in Oral “Hairy” Leukoplakia (1989) (4)
DOWNREGULATION OF THE TGF-BETA TARGET GENE , PTPRK , BY THE EPSTEIN-BARR VIRUS ENCODED EBNA 1 CONTRIBUTES TO THE GROWTH AND SURVIVAL OF HODGKIN ’ S LYMPHOMA CELLS (2007) (4)
Epstein–Barr Virus: General Features (2008) (4)
SUBTYPES OF HUMAN PAPILLOMAVIRUS 16 IN CERVICAL TISSUE (1989) (4)
TNF receptors and their ligands: in sickness and in health, in life and death (2004) (4)
Epstein-Barr Virus ( EBV )-associated Lymphoproliferative Disease in the SCID Mouse Model : Implications for the Pathogenesis of EBVpositive Lymphomas in Man (2003) (4)
Immunological studies on the Epstein-Barr virus encoded alkaline deoxyribonuclease found in virus-producing lymphoblastoid cells. (1991) (4)
Epstein-Barr Virus and Human Cancer (2002) (3)
Pathogens: A New Open Access Journal Serving All Those Interested in Infectious Disease (2011) (3)
Pituitary GnRH Receptors — Recent Studies and Their Functional Significance (1986) (3)
Gene Therapy for Colorectal Cancer (2002) (3)
Chapter 3 Role of HPV in cervical carcinogenesis (2008) (3)
Epstein-Barr Virus Gene Expression in Lymphomas Induced by the Virus in the Cottontop Tamarin (1989) (3)
Introduction: Epstein-Barr virus and non-B cell tumours. (1996) (3)
In vitro assays to study epithelial cell differentiation. (2001) (3)
Epstein-Barr Virus and Lymphomas: An Overview (1995) (2)
Physiological Regulation of Pituitary GnRH Receptors (1984) (2)
Nutritional management of the elderly. (2006) (2)
A phase I/II dendritic cell (DC) immunotherapy trial for hepatocellular carcinoma (HC) (2002) (2)
PCR for the detection of genital human papillomavirus infection: a mixed blessing. (1992) (2)
Epstein-Barr virus and epithelial cells: implications for the otolaryngologist. (1988) (2)
EPSTEIN-BARR VIRUS(HERPESVIRIDAE) | General Features (1999) (2)
Detection of Epstein-Barr virus in archival Hodgkin's disease specimens (2000) (2)
Functional Implications of Epstein-Barr Virus Lytic Genes in Carcinogenesis (2022) (2)
Immunotherapy II: Antigens, receptors and costimulation (1996) (2)
The EBV-Encoded Oncoprotein, LMP1, Recruits and Transforms Fibroblasts via an ERK-MAPK-Dependent Mechanism (2021) (2)
Aspergillus infection in the neutropenic host. (1989) (2)
Gene therapy for gastrointestinal cancer (1996) (2)
Involvement of ceramide and JNK in CD40-mediated growth inhibition. (1997) (1)
Herpesviridae: Epstein-Barr Virus (2020) (1)
Epstein-Barr virus and oncogenesis: From tumors to transforming genes (2001) (1)
Infection in marrow transplantation: problems and perspectives. (1978) (1)
Differentiation- Associated oftheEpstein-Barr Virus BZLF1Transactivator Protein inOralHairy Leukoplakia (1991) (1)
The EBV-encoded EBNA1 up-regulates macrophage migration inhibitory factor (MIF) and induces ERK signalling and the activation of Elk1 in B cell lymphoma (2008) (1)
The role of Epstein-Barr virus infection in human malignancies (2009) (1)
Distribution of Epstein-Barr Virus Strains with Different EBNA 2 Genotypes in Burkitt-Endemic Areas (1987) (1)
infection Barr virus − − independent of latent Epstein and the CD 40 ligand in Hodgkin ' s disease is Expression of B 7 ( CD 80 ) and CD 40 antigens (1)
Smoking-induced p16 methylation in young women (2010) (1)
663: Suicide Gene Therapy Using Adenovirus Encoded Nitroreductase (NTR) and CB1954 in Patients with Localized Prostate Cancer (2005) (1)
Controversial Aspects About the Management of Septic Shock (1985) (0)
Inhibition of the PI3 kinase pathway sensitises carcinoma cells to CD40-mediated apoptosis (2001) (0)
Expression of B 7 ( CD 80 ) and CD 40 antigens and the CD 40 ligand in Hodgkin ' s disease is independent of latent Epstein-Barr virus infection (2003) (0)
CD40L membrane retention enhances the immunostimulatory effects of CD40 ligation (2020) (0)
Expression of immune regulatory molecules in undifferentiated nasopharyngeal carcinomas (1995) (0)
Abstract LB-093: Activation of the FGFR1 signaling pathway by the epstein-barr virus-encoded LMP1 promotes aerobic glycolysis and transformation of human nasopharyngeal epithelial cells (2015) (0)
TRAF 6-Dependent Survival Signals 3-Dependent Death Signals and Suppression TNFR-Associated Factor ( TRAF ) Death : A Balance between Activation of CD 40 Ligand-Induced Carcinoma Cell (2009) (0)
INNOVATION VERSUS INVENTION: SERENDIPITY, CHANCE, AND EXPERIENCE FAVORING PREPARED MINDS (2017) (0)
The SH3 domain of PTTG differentially mediates FGF-2 transactivation and cell transformation (2002) (0)
Transplant infections--controversies about cost related issues. (1987) (0)
Epstein-Barr VirusTypes1and2Differ inTheirEBNA-3A, EBNA-3B,andEBNA-3CGenes (1990) (0)
EBV latent membrane protein-1 imposes a Hodgkin's lymphoma-like gene expression signature in germinal center B cells (2007) (0)
509 The polycomb group protein BMI-1 is a novel T cell antigen in human hepatocellular carcinoma (2003) (0)
Abstract 5356: Inactivation of Foxo3a and increased expression of Id1 by the Epstein-Barr Virus-encoded LMP1 facilitates resistance to TGF-β-mediated growth inhibition in nasopharyngeal epithelial cells (2010) (0)
Systematic Review of HIV Prevention and Intervention Programs for Black Men Who Have Sex With Men: (616012009-001) (2009) (0)
tissue . hybridisation in paraffin wax embedded primary brain lymphoma by in situ DNA Demonstration of Epstein-Barr virus in (0)
Corrigendum to "A Phase I/II Clinical Trial in Localized Prostate Cancer of an Adenovirus Expressing Nitroreductase With CB1984". (2009) (0)
Early B Cells Immortalized by Epstein-Barr Virus (EBV) - A Phenotypic Study (1988) (0)
ACTIVATION OF CD40 ON HUMAN HEPATOCYTES INCREASES FAS LIGAND EXPRESSION AND INDUCES APOPTOSIS: A NOVEL MECHANISM OF HEPATOCYTE LOSS IN LIVER ALLOGRAFT REJECTION: (1998) (0)
Augments Chemotherapy-Induced Apoptosis Cells Facilitates CTL Responses and Activation of CD40 in Cervical Carcinoma (2004) (0)
Pathogens: Journal Section Readjustment (2021) (0)
EBV latent gene expression in Hodgkin's disease: implications for tumour development and immunotherapy (1995) (0)
Epstein-Barr Virus-Encoded LMP1 Regulates Epithelial Cell Motility and Invasion via the ERK-MAPK Pathway (cid:1) (2008) (0)
Author Correction: Whole-genome profiling of nasopharyngeal carcinoma reveals viral-host co-operation in inflammatory NF-κB activation and immune escape (2022) (0)
Combined suicide gene therapy and oncolytic viral therapy for prostate cancer (2002) (0)
CD40 in CIN and cervical cancer: An immunohistochemical analysis revealing an intriguing expression profile (2000) (0)
Gene Therapy for Cancer: Prospects for the Treatment of Lung Tumours (1999) (0)
Survival in Hodgkin's Disease Effect of Epstein-Barr Virus Infection on Response to Chemotherapy and (2013) (0)
Epstein–Barr Virus (Herpesviridae) (2021) (0)
DEMONSTRATION OF EPSTEIN-BARR VIRUS IN PARIMARY CENTRAL NERVOUS SYTEM LYMPHOMAS. AUTHOR'S REPLY (1991) (0)
Infections in patients with cellular immunodeficiency. (1989) (0)
Expression and function of costimulatory molecules in human hepatocellular carcinoma (2000) (0)
Session 8: Liver immunology: roles in malignancy (2004) (0)
Enhances the Cytotoxicity of Fas Ligand Inhibition of Metalloproteinase Cleavage (2002) (0)
Epstein-Barr Virus: Nasopharyngeal Carcinoma and Other Epithelial Tumors (2014) (0)
EBV AND APOPTOSIS: VIRAL MIMICRY OF CELLULAR PATHWAYS (1999) (0)
Epstein-Barr Virus Infection: From Persistence to Pathogenesis (2008) (0)
Nasopharyngeal Carcinoma (2019) (0)
ctive , antimetastatic and anti-cancer stem cell metallohelices via post-assembly modi fi cation † (2019) (0)
Pathogens Best Paper Awards for 2015 (2015) (0)
biopsylike Burkitt lymphoma cells Population depletion activates autonomous CD154-dependent survival in (2013) (0)
CD8+ T Cell Responses to the Polycomb Protein EZH2 in Patients with Haemopoietic Malignancies. (2005) (0)
CD40 INDUCED Fas‐L EXPRESSION MAY CONTRIBUTE TO THE LOSS OF BILE DUCTS BY APOPTOSIS IN CHRONIC ALLOGRAFT REJECTION.: Abstract# 28 (2000) (0)
Transcripts fromtheEpstein-Barr Virus BamHIA Fragment AreDetectable inAllThreeFormsofVirusLatency (1993) (0)
256 Dendritic cell vaccination for hepatocellular carcinoma (2003) (0)
Loughborough University Institutional Repository The Epstein-Barr virus encoded LMP 1 oncoprotein modulates cell adhesion via regulation of activin A / TGF β and β 1 integrin signalling (2019) (0)
Prophylaxis of infection in granulocytopenic patients. (1985) (0)
Disruption of the SH3 domain of pituitary tumor transforming gene (PTTG) reveals distinct mechanisms of FGF-induction and cell transformation (2002) (0)
Differential activation of NF-kB and AP-1 transcription factors may regulate hepatic epithelial and endothelial cell survival following CD40 ligation (2001) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Lawrence S Young?

Lawrence S Young is affiliated with the following schools:

Lawrence S Young's Academic­Influence.com Rankings

Lawrence S Young's Degrees

Similar Degrees You Can Earn

Why Is Lawrence S Young Influential?

Lawrence S Young's Published Works

Published Works

What Schools Are Affiliated With Lawrence S Young?

Lawrence S Young's AcademicInfluence.com Rankings